Insulin Toujeo® — a Novel Basal Long-Acting Insulin Formulation Part 1. Pharmacokinetic and Pharmacodynamic Aspects

Abstract

This review, consisting of two parts, considers a new formulation of insulin glargine (rDNA origin) in the form of injections 300 U/ml (Gla-300, Toujeo®). Gla-300 is a next generation basal insulin with a novel formulation of insulin glargin delivering the same amount of insulin, as glargine-100 (Gla-100, Lantus®) in 1/3 volume. Following the subcutaneous injection, pharmacokinetic and pharmacodynamic profiles of Gla-300 are more constant and prolonged (beyond 24 hours) compared with Gla-100 due to a more gradual and extended release of glargine from subcutaneous depot (Gla-300 forms a more compact subcutaneous depot with reduced surface area compared to Gla-100). The clinical efficacy and safety of Gla-300 in patients with type 1 and type 2 diabetes mellitus are discussed with an emphasis on recently released data from EDITION (the phase 3a) clinical trials. Gla-300 showed comparable glycaemic control and similar safety profile with lower incidence of hypoglycaemia events compared with Gla-100. Gla-300 provided flexible dosing of insulin (24 ± 3 h or morning vs evening) and was associated with less body weight gain.

Authors and Affiliations

V. V. Poltorak, N. A. Kravchun, M. Yu. Gorshunska

Keywords

Related Articles

Prevalence and structure of thyroid diseases in children and adolescents according to the data of appealability

Background. Thyroid pathology in children and adolescents is a topical problem of endocrinology. The purpose was to study the incidence and structure of thyroid pathology in children and adolescents from data of 2012–201...

Ultrasound Densitometry in the Diagnosis of Disorders of Bone Mineral Density in Patients with Thyroid Pathology

The objective of this study was to establish the relationship between the levels of thyroid hormones and characteristics of bone tissue according to radiological and laboratory methods. To assess the influence of thyroid...

Evaluation of Clinical and Metabolic Parameters of Efficiency of Long-term Training and Achievement of Target Levels of Type 1 Diabetes Mellitus Therapy in Children and Adolescents

For five years, we have examined two groups of sick children and adolescents with diabetes mellitus type 1. The main group with training accounted for 92 children and adolescents with self-management training by a specia...

Analysis of the prevalence of thyroid pathology during gestation among women from Lviv region

ackground. The unified theory of iodine deficiency does not provide a comprehensive coverage of the etiological and pathogenetic essence of goiter transformation. It was found that in areas with the same level of iodine...

The Meaning of Using «The Quality of Life Assessment of Growth Hormone Deficiency in Adults» Questionnaire in Patients with Non-Functional Pituitary Adenomas and Various Tumors of Chiasmosellar Area in Pre- and Postoperative Period

The authors have examined 136 patients with growth hormone deficiency (GHD) of various origins (pituitary tumors and ischemic heart disease — comparison group). The investigation of the quality of life on the basis of GH...

Download PDF file
  • EP ID EP215662
  • DOI -
  • Views 150
  • Downloads 0

How To Cite

V. V. Poltorak, N. A. Kravchun, M. Yu. Gorshunska (2015). Insulin Toujeo® — a Novel Basal Long-Acting Insulin Formulation Part 1. Pharmacokinetic and Pharmacodynamic Aspects. Міжнародний ендокринологічний журнал, 7(71), 22-35. https://europub.co.uk/articles/-A-215662